Propofol in chemotherapy-associated nausea and vomiting

Propofol appears to possess antiemetic actions. Limited reports have shown benefit with its use as adjuvant therapy with highly emetogenic chemotherapy regimens and as monotherapy with moderately emetogenic chemotherapy. Adverse effects have been minimal. It should be noted that to date no Phase I dose ranging studies have been described; therefore, optimal dose and duration remain unknown. Results from well-designed, controlled clinical trials in large numbers of patients are needed to define the appropriate role of propofol in antiemetic therapy. Currently, propofol must be reserved for use in clinical trials or as adjuvant therapy for patients refractory to standard 5-HT3 antagonist and corticosteroid antiemetic prophylaxis.